A NON-RANDOMIZED, OPEN LABEL, SAFETY AND EFFICACY STUDY EVALUATING KAMUVUDINE-8 (K8) FOR THE TREATMENT OF PATIENTS WITH GEOGRAPHIC ATROPHY
Latest Information Update: 13 Apr 2025
At a glance
- Drugs Kamuvudine 8 (Primary)
- Indications Dry macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Acronyms K8 for GA
Most Recent Events
- 15 Jan 2025 According to an Inflammasome Therapeutics media release, company announced Positive efficacy and safety data were observed at 3 months after a single injection of K8 in this study conducted at the University of Kentucky
- 15 Jan 2025 Results published in the Inflammasome Therapeutics media release
- 05 Dec 2024 Planned End Date changed from 1 Apr 2025 to 1 Dec 2025.